These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33495404)

  • 1. Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma.
    Yuan W; Tao R; Huang D; Yan W; Shen G; Ning Q
    Aging (Albany NY); 2021 Jan; 13(3):3969-3993. PubMed ID: 33495404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma.
    Zhang S; Guo H; Wang H; Liu X; Wang M; Liu X; Fan Y; Tan K
    Apoptosis; 2024 Jun; 29(5-6):768-784. PubMed ID: 38493408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated Transcriptomic Analysis Revealed Hub Genes and Pathways Involved in Sorafenib Resistance in Hepatocellular Carcinoma.
    Jiang X; Zhang W; Li L; Xie S
    Pathol Oncol Res; 2021; 27():1609985. PubMed ID: 34737677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of hepatocellular carcinoma that responds differently to combination therapy with TACE and Sorafenib as determined by digital spatial gene expression profiling.
    Xu C; Su R; Lu Z; Song Y; Zhang X; Shu W; Yang Z; Zhuang R; Xu X; Wei X
    Genes Genomics; 2024 Sep; 46(9):1045-1058. PubMed ID: 39078588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BAFF/NFκB axis is crucial to interactions between sorafenib-resistant HCC cells and cancer-associated fibroblasts.
    Gao L; Morine Y; Yamada S; Saito Y; Ikemoto T; Tokuda K; Miyazaki K; Okikawa S; Takasu C; Shimada M
    Cancer Sci; 2021 Sep; 112(9):3545-3554. PubMed ID: 34159680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy.
    Zhou S; Liu Y; Zhang Q; Xu H; Fang Y; Chen X; Fu J; Yuan Y; Li Y; Yuan L; Xiang C
    Stem Cell Res Ther; 2023 Apr; 14(1):58. PubMed ID: 37005657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing
    Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
    Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3.
    Kong H; Sun J; Zhang W; Zhang H; Li H
    Bioengineered; 2022 Feb; 13(2):3108-3121. PubMed ID: 35037556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
    Marisi G; Cucchetti A; Ulivi P; Canale M; Cabibbo G; Solaini L; Foschi FG; De Matteis S; Ercolani G; Valgiusti M; Frassineti GL; Scartozzi M; Casadei Gardini A
    World J Gastroenterol; 2018 Sep; 24(36):4152-4163. PubMed ID: 30271080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.
    Sui C; Dong Z; Yang C; Zhang M; Dai B; Geng L; Lu J; Yang J; Xu M
    J Cell Mol Med; 2019 Sep; 23(9):6024-6033. PubMed ID: 31210410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
    Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
    Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma.
    Xiao H; Chen H; Zhang L; Duolikun M; Zhen B; Kuerban S; Li X; Wang Y; Chen L; Lin J
    World J Surg Oncol; 2024 Jun; 22(1):152. PubMed ID: 38849867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
    Guo Z; Zhang J; Fan L; Liu J; Yu H; Li X; Sun G
    Med Sci Monit; 2019 Mar; 25():2079-2086. PubMed ID: 30893293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines.
    Zhang Z; He CZ; Qin YQ; Liao JJ; Huang ST; Mo S; Li HM; Lin JY
    Aging (Albany NY); 2020 Nov; 12(23):24255-24269. PubMed ID: 33234725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7.
    Feng X; Zou B; Nan T; Zheng X; Zheng L; Lan J; Chen W; Yu J
    Int J Med Sci; 2022; 19(2):257-266. PubMed ID: 35165511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
    Tovar V; Cornella H; Moeini A; Vidal S; Hoshida Y; Sia D; Peix J; Cabellos L; Alsinet C; Torrecilla S; Martinez-Quetglas I; Lozano JJ; Desbois-Mouthon C; Solé M; Domingo-Domenech J; Villanueva A; Llovet JM
    Gut; 2017 Mar; 66(3):530-540. PubMed ID: 26658144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-scale CRISPR activation screening identifies a role of LRP8 in Sorafenib resistance in Hepatocellular carcinoma.
    Cai J; Chen J; Wu T; Cheng Z; Tian Y; Pu C; Shi W; Suo X; Wu X; Zhang K
    Biochem Biophys Res Commun; 2020 Jun; 526(4):1170-1176. PubMed ID: 32312520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.